礼来宣布计划在荷兰卡特维克投资30亿美元新建生产基地,以扩大口服药物产能,完善公司全球供应链体系。该生产基地将承担其首款口服小分子GLP-1受体激动剂orforglipron的生产任务。公司计划于今年年底前向全球监管机构提交该药物的肥胖症治疗申请。礼来同时表示,该投资计划将为南荷兰省创造500个高薪岗位,招聘对象包括高技能工程师、科学家、运营专员及实验室技术人员。此外,预计建设期间将新增约1500...
Source Link礼来宣布计划在荷兰卡特维克投资30亿美元新建生产基地,以扩大口服药物产能,完善公司全球供应链体系。该生产基地将承担其首款口服小分子GLP-1受体激动剂orforglipron的生产任务。公司计划于今年年底前向全球监管机构提交该药物的肥胖症治疗申请。礼来同时表示,该投资计划将为南荷兰省创造500个高薪岗位,招聘对象包括高技能工程师、科学家、运营专员及实验室技术人员。此外,预计建设期间将新增约1500...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.